Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Raul Rodriguez | M | 63 | 24 years | |
David Apelian | M | 59 | 7 years | |
Adrian Adams | M | 73 | 11 years | |
Thomas Dietz | M | 60 | 8 years | |
Evan Loh | M | 65 | 7 years | |
Richard A. Franco | M | - | 8 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Eldon Mayer | M | 62 | 6 years | |
Sriram Ryali | M | 43 | 5 years | |
James Shannon | M | 68 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 1 years |
Gary Patou | M | 65 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 3 years |
Thomas A. Schreck | M | 67 | 8 years | |
Gary Lyons | M | 73 | 19 years | |
Paul Sekhri | M | 66 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 5 years |
Dolly Vance | F | 59 | 22 years | |
Nina Kjellson | F | 49 | 1 years | |
Ryan Maynard | M | 54 | 16 years | |
Richard Afable | M | 70 | 11 years | |
Timothy Morris | M | 62 | 3 years | |
Guy Nohra | M | 63 | 7 years | |
Mark G. Edwards | M | 66 | 11 years | |
Hollings Renton | M | 77 | 10 years | |
Charles Bramlage | M | 63 | 2 years | |
Kimberley Gaumer | F | - | - | |
Edgar Engleman | M | 78 | 1 years | |
Peter S. Ringrose | M | 78 | 14 years | |
David Scott Geyer | M | 65 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | - |
Stephen Sherwin | M | 75 | 17 years | |
Matthew J. Meyer | M | 54 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 2 years |
Francesco Parlati | M | 55 | 2 years | |
David H. Chung | M | - | 1 years | |
Charles Rampersaud | M | - | 6 years | |
William Callahan | M | 65 | - | |
Joanne Quan | M | 60 | - | |
Shelly Xiong | M | - | - | |
Christopher Whitmore | M | - | 4 years | |
Debra A. Odink | M | 60 | - | |
Ayse Kocak | F | - |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | - |
Mike A. Royal | M | 70 | 2 years | |
Garry Nolan | M | 63 | 6 years | |
Mark K. Bennett | M | 65 | 4 years | |
John B. Kaiser | M | 88 | 8 years | |
Susan Molineaux | M | 70 | 3 years | |
Natalie L. McClure | M | 71 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 3 years |
Elliott B. Grossbard | M | 76 | 14 years | |
Nicholas Simon | M | 67 | - | |
Daniel J. Levitt | M | 76 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 2 years |
Dennis J. Henner | M | 72 | - | |
Scott T. Shearer | M | 59 |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | 2 years |
Martin V. Mulroy | M | 63 | 1 years | |
Robin D. G. Cooper | M | 85 | - | |
Garry Nolan | M | - | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 49 | 96.08% |
Canada | 2 | 3.92% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Welch
- Personal Network